Fully-humanized neutralizing monoclonal antibody for resisting cofda virus as well as preparation method and application of fully-humanized neutralizing monoclonal antibody

By selecting and expressing fully human antibodies from patients recovering from SFTS, the problem of insufficient specific treatment drugs and detection methods for DBV infection has been solved. It achieves highly efficient neutralizing activity and specific binding, making it suitable for clinical application.

CN121824744APending Publication Date: 2026-04-10JIANGSU PROVINCIAL BLOOD CENT (JIANGSU PROVINCIAL INST OF MEDICAL & BIOLOGICAL PROD)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-26
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

There is currently no specific treatment for Dabie Bandar virus (DBV) infection. Existing antibodies have high immunogenicity, and DBV detection methods have shortcomings such as insufficient specificity and reliance on specialized equipment.

Method used

Single B cells marked with CD19+, IgG+, and CD27+ and capable of binding to Dabie Bandar virus Gn protein were isolated from peripheral blood mononuclear cells of patients in the recovery period of fever with thrombocytopenia syndrome. The gene sequences of the heavy chain and light chain variable regions were obtained by B cell receptor sequencing, cloned into expression vectors, and recombinant expression plasmids were constructed. The fully human antibody was then expressed and purified in eukaryotic cells.

Benefits of technology

It provides a fully human antibody with high specificity and high neutralizing activity, which can significantly block DBV virus infection of host cells with an inhibition rate of 94.1%, providing an important guarantee for the treatment of DBV infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121824744A_ABST
    Figure CN121824744A_ABST
Patent Text Reader

Abstract

The invention relates to a fully human neutralizing monoclonal antibody for resisting a large allofanda virus as well as a preparation method and application of the fully human neutralizing monoclonal antibody. An amino acid sequence of a heavy chain variable region of the antibody is shown as SEQ ID NO.3, an amino acid sequence of a light chain variable region of the antibody is shown as SEQ ID NO.4, and the antibody can be specifically combined with glycoprotein Gn of DBV and has virus neutralizing activity. The preparation method comprises the following steps: sorting antigen-specific B cells from peripheral blood of a patient in the recovery phase of the severe fever with thrombocytopenia syndrome, carrying out single cell BCR sequencing to obtain an antibody gene sequence, and carrying out recombinant expression and purification through an eukaryotic expression system. The antibody can be used for preparing an immunodetection reagent for detecting a DBV antigen or developing a medicine for treating DBV infection related diseases.
Need to check novelty before this filing date? Find Prior Art